

gellerbiopharm

Office (212) 315-0600

Web gellerbp.com

Broker / Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA/ SIPC

Summary

Personal

Diverse, world-class team of top biotech bankers, business & research development, industry and international healthcare consultants. Senior bankers execute all aspects of the engagement, from initial pitch to closing dinner, without handoff or bureaucracy

Financing

Vast experience in stock placement, with long term personal relationships with venture capital and key crossover funds in the US and Europe

LM&A

Employ multiple track global and regional strategies, enhanced by outstanding capabilities in positioning and presenting companies to increase receptiveness by target audience, to encourage competitive bidding for our clients

Network


True access to global leaders in pharma, biotech, specialty pharma, diagnostics, devices and CRO companies. Culled through years of collaborative work and personal relationships, network includes CEO's, CFO's, CSO's and Heads of Business & Research Development, in addition to top-tier buy side firms

Core Services

Broad Scope



Strong Relationships



Team

Matthew Geller, PhD Managing Director



Contact Me

 matt@gellerbp.com

 o (212) 315-0600

Matthew Geller is the founder of Geller Biopharm. Founded in 2008, Geller Biopharm has performed numerous M&A and advisory transactions as a consultant and is a registered representative with the Pickwick Capital Partners, LLC.

Dr. Geller was previously head of healthcare banking at Rodman and Renshaw from 2006-2008. Throughout this period, the group was consistently ranked #1 on the Street for PIPES and registered directs, according to Sagient Research Systems. Dr. Geller was also responsible for M&A and advisory assignments for both public and private biotech companies.

From 1994-2005, Dr. Geller was Managing Director and Senior Biotechnology Analyst at Oppenheimer and CIBC World Markets. Dr. Geller was named one of the best stock-pickers in biotechnology in the Wall Street Journal's Best on the Street Analysts Survey, was selected by Institutional Investor magazine as a member of its All-Star Home-Run Hitters research team and has been a member of the publication's All-America Research team. He consistently had the #1 rating for client service.

Dr. Geller was also a television writer for a number of well-known shows: The Cosby Show, Married with Children, and The Facts of Life. Earlier in his career, Dr. Geller was a professor at University of California Berkeley, the University of Michigan, Ann Arbor and Duke University. He was published extensively.

Dr. Geller earned a BA in mathematics from Yale, a Master's in mathematics from U.C. San Diego, and a Ph.D. in computer science from the U.C. Berkeley. Further, he is fluent in French and German. Dr. Geller is a registered representative with the Pickwick Capital Partners, LLC.

Team

Avi Holchendler, MD Executive Director



Avi Holchendler leverages his experience and education to provide clients with an unparalleled level of industry-specific financial leadership. Dr. Holchendler has managed multiple biotech LM&A and advisory and financing engagements since joining Geller Biopharm. He has also formalized strategic partnerships with members of the Paris-based Publicis Healthcare Consulting group, and NYC-based The Frankel Group, two life science consulting firms with expertise in due diligence and global partnerships, to broaden the expertise available to our clients.

Prior to joining Geller Biopharm, was an Associate at the Frankel Group, a boutique management consulting firm in New York City and Cambridge, Massachusetts that has served the life science industry and related segments since 1993.

Dr. Holchendler graduated summa cum laude from Yeshiva University with a BA degree in psychology. He earned his MD with distinction from the Albert Einstein College of Medicine.

Dr. Holchendler is a registered representative with the Pickwick Capital Partners, LLC.

Contact Me

 avi@gellerbp.com

 o (212) 315-0600

Team

Jessica Sigall

Director, Institutional Sales



Jessica Sigall is the Director of Institutional Sales and Operations at Geller Biopharm, where she manages marketing, investor relations, and day-to-day operations. Geller Biopharm is an investment bank that serves biotechnology (biotech) and pharmaceutical (pharma) clients with licensing, M&A, financial restructuring, and advisory services.

Prior to joining Geller, Ms. Sigall ran operations at a prominent women's swimwear line. She is a summa cum laude graduate of Barnard College, where she majored in Economics and was elected to the Phi Beta Kappa honor society. Ms. Sigall obtained her MBA in Entrepreneurship from the Zicklin School of Business, Baruch College.

She is involved in numerous young leadership charitable events in New York City. She is also a registered representative with the Pickwick Capital Partners, LLC.

Contact Me

 jessica@gellerbp.com

 o (212) 315-0600

Licensing, Mergers & Acquisitions

Summary

The senior members of Geller Biopharm are personally involved in every stage of the engagement, from the initial meeting to closing dinner.

Based on many years of experience, Geller Biopharm has outstanding capabilities in positioning and presenting companies to increase the receptiveness by the appropriate target audience.

Our team has enormous breadth and depth in its industry contacts with senior executives, heads of business and research development.


Geller Biopharm's objective is to reach out to a broad array of targets in seeking multiple term sheets to encourage competitive bidding for our clients.

We employ both global and regional LM&A strategies, with strong relationships with European and Asian companies.

Our advisors increase our reach into the global market and add strategic due diligence and market analysis capabilities.

Licensing, Mergers & Acquisitions

Process



Licensing, Mergers & Acquisitions

Additional Strategies

Regional Licenses

Successful strategy that allow companies to retain certain territorial rights to their compounds while providing capital to fund development of lead assets. Asian carve out strategies are popular; Geller Biopharm has strong relationships with both Japanese and Korean companies seeking licenses.

Reverse Mergers

Combine a private company with an exciting product and/or platform with a public company with cash or trading near or below cash. Geller Biopharm has successfully executed reverse merger transactions for its clients and is a viable strategy when the IPO window is closed.

Proprietary In-Licensing

Geller Biopharm, in conjunction with the Frankel Group, offers a proprietary product for systematically identifying and acquiring novel compounds or companies utilizing a comprehensive array of resources.

Senior members of our team work in close conjunction with our clients, to conduct an initial broad scientific and commercial review of targeted therapeutic area(s), and build a list of appropriate companies and products for acquisition.

Leveraging our global relationships, Geller Biopharm helps guide internal due diligence, deal structure and execution with targeted compounds/companies.

Financing

Summary

Vast experience in private and public financing, including venture and crossover financings, PIPES, Registered Directs, Secondaries and IPO's.


Long-term personal relationships with a broad array of US and European public and private investors.

Based on many years of experience, Geller Biopharm has outstanding capabilities in positioning and presenting companies to the investor audience for financing.

The senior members of Geller Biopharm are personally involved in every stage of the engagement, from the initial meeting to closing dinner.

Financing

Process



Select Transactions



Financing
2020



Advisor
2019



Advisor
2019



Advisor
2019



Advisor
2019



Advisor
2019



Advisor
2019



Advisor
2019



License To



2019



Advisor
2018



Advisor
2018



Advisor
2018



License To



2018



License To



2018



Sale of Royalties
To



2018

Select Transactions



License To



December 2017



Sale To



2017



Fairness Opinion

2017



Global License
Gaboxadol from



March 2015



\$50,000,000
Initial Public Offering
Co-Manager

June
2014



\$52,000,000
Public Offering
Advisor

February 2014



Global
License
License
CPP1X/Sul to



January 2014



\$5,800,000 PIPE
Advisor

April 2013



\$5,000,000 PIPE
Co-Placement Agent

April 2013

gellerbiopharm

Contact Us

Office (212) 315-0600

Fax (212) 315-0077

Web gellerbp.com

Broker / Dealer services provided by Pickwick Capital Partners, LLC.
Member FINRA/SIPC

Address

142 West 57th Street
11th Floor
New York, New York 10019

